In Vivo Molecular Effects of Aspirin on Prostate Tissue
Prostate cancer is the most common non-cutaneous malignancy in men and is the second leading
cause of cancer death among U.S. men. 221,000 new cases and 29,000 deaths are expected in
2003. The incidence of prostate cancer diagnosis is increasing at 3% per year. Prostate
specific antigen (PSA) screening has resulted in improvements in early diagnosis of prostate
cancer. However, available treatments all may have a significant negative effect on quality
Studies have implicated a beneficial association between ASA use and a lower risk of other
types of malignancies, including stomach, esophageal, breast, ovarian, and prostate cancer.
There is significant evidence to suggest that aspirin has a protective effect against
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Assess the effect of oral aspirin on in vivo prostate epithelial cells.
Daniel W Lin, MD
Veteran's Administration Puget Sound Health Care Service
United States: Institutional Review Board
|VA Puget Sound Health Care Service||Seattle, Washington 98108|